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ABSTRACT Inhaled hypertonic saline (HS) is an effective therapy for muco-obstructive lung diseases.
However, the mechanism of action and principles pertinent to HS administration remain unclear.
An in vitro system aerosolised HS to epithelial cells at rates comparable to in vivo conditions. Airway
surface liquid (ASL) volume and cell height responses were measured by confocal microscopy under
normal and hyperconcentrated mucus states.
Aerosolised HS produced a rapid increase in ASL height and decrease in cell height. Added ASL volume
was quickly reabsorbed following termination of nebulisation, although cell height did not recover within
the same time frame. ASL volume responses to repeated HS administrations were blunted, but could be
restored by a hypotonic saline bolus interposed between HS administrations. HS-induced ASL hydration
was prolonged with hyperconcentrated mucus on the airway surface, with more modest reductions in cell
volume.
Aerosolised HS produced osmotically induced increases in ASL height that were limited by active
sodium absorption and cell volume-induced reductions in cell water permeability. Mucus on airway
surfaces prolonged the effect of HS via mucus-dependent osmotic forces, suggesting that the duration of
action of HS is increased in patients with hyperconcentrated mucus.
This article has supplementary material available from erj.ersjournals.com




The effectiveness of mucociliary clearance is heavily dependent on adequate hydration of mucus. Under
normal circumstances, airway epithelial cells have the capacity to absorb and secrete ions via active ion
transport, with movement of water governed by transepithelial osmotic gradients. The net effect of this
balance between secretion and absorption is to maintain mucus layer hydration at levels adequate to
promote efficient mucus clearance [1]. Hyperconcentrated mucus, with failed mucus clearance, is
characteristic of many muco-obstructive diseases, including cystic fibrosis (CF) [2], primary ciliary
dyskinesia [3] and non-CF bronchiectasis [4].
Aerosolised hypertonic saline (HS) is an effective therapy in adults with CF [5, 6] and non-CF
bronchiectasis [7, 8], producing improvements in mucociliary clearance, forced expiratory volume in 1 s
and quality of life. Despite its clinical utility, the mechanism of action of HS remains speculative.
Accelerating mucociliary clearance via electrostatic interactions with mucins [9], expanding airway surface
liquid (ASL) hydration [10] or inhibiting epithelial sodium channels (ENaC) [9] have been proposed as
mechanisms. Most mechanistic studies deposited large volumes of HS onto human bronchial epithelial
(HBE) surfaces and have not mimicked in vivo aerosol deliveries. Furthermore, most studies using cultured
HBE cells were performed without endogenous normal (2% solids) or hyperconcentrated (∼8% solids)
mucus on HBE surfaces [5, 10].
As prescribed for clinical use, HS is aerosolised to the lower airway surfaces in small (nL·cm−2·min−1)
volumes over protracted intervals (∼15 min). In this study, an in vitro aerosolisation system was developed
to mimic in vivo aerosol delivery rates to airway epithelia that exhibited a range of mucus concentrations,
spanning “normal” to muco-obstructive conditions. The primary goal was to characterise the kinetics of
HS effects on airway surface hydration. The ancillary goal was to identify strategies to improve the efficacy
of HS in the treatment of lung disease. Because of the great diversity of nebulisers and HS strengths used
in clinical practice, and the fact that the osmotic effectiveness of HS depends on the rate of sodium
chloride (NaCl) delivery to airway surfaces, our studies are described in µg NaCl deposited cm−2·min−1,
rather than percentage HS at a given deposition rate. Some of these data have been reported previously in
the form of an abstract [11–15].
Methods
Full details of the methods are provided in the online supplementary material.
HBE cultures and apical mucus content
Primary HBE cells generated from cells isolated from explanted lungs were maintained at an air–liquid
interface until fully differentiated. Culture surfaces were washed daily to produce HBE cultures with small
amounts of residual mucus that mimicked normal epithelia, whereas HBE preparations with the mucus
layer left unwashed for 2 weeks were generated to produce higher mucus compositions.
Confocal measurements of ASL
Primary HBE cells were labelled with 2.0 µM calcein-AM (Invitrogen, Carlsbad, CA, USA) basolaterally.
ASL was visualised by adding a 5 µL of Texas red dextran (70000 MW, 5 mg·mL−1; Invitrogen) luminally.
HS (7%) solution was aerosolised utilising a vibrating mesh nebuliser (Aeroneb Lab; Aerogen, Galway,
Republic of Ireland), modified to deliver small volumes (nL·min-1). Nebulisers were cleaned daily in
accordance with Cystic Fibrosis Foundation guidelines and tested periodically for functionality. The system
was mounted in an environmental chamber that controlled air currents and regulated temperature at 37°C,
humidity at >50% and carbon dioxide at 5%, interfaced to a scanning confocal microscope (SP5; Leica,
Wetzlar, Germany). Cell and ASL heights were measured by high-speed XZ confocal scanning. Following
baseline imaging, 7% HS was nebulised to apical surfaces of HBE cells at the prescribed rate and effects
were measured at 30-s intervals.
ELISA determination of interleukin-8 secretion
Production of interleukin (IL)-8 in HBE was measured 24 h after nebulising either 3, 8 or 18 µg
NaCl·cm−2·min−1 or sham nebulisation of PBS (control). For comparison, parallel cultures were treated
with a bulk addition of hypertonic saline (100 µL 7% solution). Concentrations of IL-8 in the culture
medium were measured using a human IL-8 ELISA kit (R&D Systems, Minneapolis, MN, USA) according
to the manufacturer’s protocol. Briefly, after incubation, the culture medium was removed. Samples and
standards were added to wells of microplates precoated with an anti-human IL-8 monoclonal antibody
and incubated for 2 h. Each well was washed and incubated with the enzyme-linked polyclonal antibody
specific for human IL-8 for 2 h. The wells were washed to remove unbound antibody-enzyme reagent,
substrate solution added to each well for 20 min at room temperature, the enzyme reaction was stopped,
and IL-8 concentrations determined by comparison of the optical density results with the standard curve.
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Mathematical modelling
The airway fluid transport model of WARREN et al. [16] was utilised in the construction of an integrative
model of human airway ion and fluid transport [17, 18]. This model solves an ordinary differential
equation system for membrane potentials (Va, Vb), intracellular sodium, chloride and potassium ion
concentrations ([Na+]i, [Cl−]i, [K+]i, respectively), extracellular ion concentrations ([Na+]e, [Cl−]e, [K+]e)
and extracellular and intracellular fluid volumes (We, Wi) [18]. For the HS simulations, water with a high
concentration of NaCl was “added” to the apical surface for designated volumes.
Statistical analysis
All data analyses and graphing were performed in SigmaPlot (Systat Software, San Jose, CA, USA). Mean
values were compared via one-way ANOVA, with Holm–Sidak method for pairwise multiple comparisons
in statistically significant findings. For non-normal data, the Kruskal–Wallis one-way ANOVA was used,
with multiple groups compared via the Dunn method. Paired t-tests or Mann–Whitney rank sum tests
were used where appropriate.
Results
The first series of studies focused on the effect of HS on HBE cultures with “normal” mucus
concentrations (1.9±1.7% solids) on apical surfaces. HS was delivered to HBE cultures for 15 min at a rate
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FIGURE 1 a) XZ-confocal image of a cross-section of airway epithelial cells stained with calcein, a fluorescent
green dye, and airway surface liquid (ASL) stained with Texas red dextran, a cell-impermeable red dye;
b) after administration of an osmotic stimulus (hypertonic saline (HS)), there is an increase in ASL height
along with a decline in cell height; c) HS aerosolised to the surface of human bronchial epithelial cultures
(8 µg NaCl·cm−2·min−1 for 15 min) results in a significant transient increase in ASL height, lasting <1 h. n=8
for each experiment.
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of 8 µg NaCl·cm−2·min−1 (7% HS delivered at 110 nL·cm−2·min−1) to mimic a standard jet nebuliser
delivery rate for human subjects (online supplementary material). A rapid and significant increase in ASL
height was observed, reflecting the osmotic-driven transepithelial fluid flow in response to deposited HS
[19] (figure 1). Net reabsorption of the osmotically expanded ASL began immediately after nebulisation
was terminated, and ASL height returned to baseline height within 60 min after aerosol initiation.
In clinical practice, jet nebulisers typically deliver HS in a 4 mL dose over ∼15 min, whereas vibrating
mesh nebulisers deliver the same volume in ∼5 min. To address whether HS delivery rates affect ASL
volume responses, a constant total mass of salt was nebulised onto the HBE surface at varying nebulisation
rates and, hence, durations of nebulisation. The rates selected for study were designed to a mimic delivery
of 7% HS via jet nebuliser (8 µg NaCl·cm−2·min−1), a vibrating mesh nebuliser (18 µg NaCl·cm−2·min−1)
and an arbitrarily defined “slow” nebuliser (3 µg·cm−2·min−1) (figure 2a). Both the 8 and 18 µg
NaCl·cm−2·min−1 rates produced rapid and significant increases in ASL height. The response of cultures to
the 3 µg NaCl·cm−2·min−1 rate was considerably smaller with respect to ASL volume expansion, but longer
due to the extended nebulisation duration. All cultures, irrespective of nebulisation rate, rapidly absorbed
the added volume from the ASL once nebulisation was terminated.
Areas under the curves (AUCs) of the ASL height data were calculated as an index of “hydration activity”
of the nebulised solution. Interestingly, faster salt deposition (18 µg·cm−2·min−1) produced a lower, though
not statistically different, total ASL hydration compared to standard jet nebuliser rates (8 µg·cm−2·min−1).
Slower aerosol deposition (3 µg·cm−2·min−1) produced trends towards lower peak and AUC values
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FIGURE 2 Effects of variation in hypertonic saline (HS) delivery rates on airway surface liquid (ASL) volume responses. a) Comparison of ASL
heights achieved with three rates of nebulised HS (low 3 µg NaCl·cm−2·min−1; moderate 8 µg NaCl·cm−2·min−1; and high 18 µg NaCl·cm−2·min−1)
with duration varied to hold constant total delivered mass of salt. Isotonic saline shown as control. p<0.05 for all groups compared to isotonic
saline control. b) Both absolute height change and total hydration (integrated area over time) favoured the mid-range dosing regimen, but did not
reach statistical significance (p=0.373). c, d, e) Theoretical heights indicate the expected rise in ASL height if all salt deposited resulted in an
equimolar flux of water into the ASL. Experimental ASL height lines indicate the actual change in ASL height observed during experiments. The
failure of these two lines to overlay indicates an inhibition of the transport of water from the epithelial cells into the ASL. c) Low-dose nebulisation
(3 µg NaCl·cm−2·min−1): theoretical slope 4.72 µm·min−1 versus experimental slope of 0.45 µm·min−1 (p<0.001); d) medium-dose nebulisation (8
µg NaCl·cm−2·min−1): theoretical slope 14.92 µm·min−1 versus experimental slope of 8.66 µm·min−1 (p<0.001); e) high-dose nebulisation (18 µg
NaCl·cm−2·min−1): theoretical slope 51.49 µm·min−1 versus experimental slope of 20.78 µm·min−1 (p<0.001). n=4 per experimental condition.
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Assuming no active Na+-mediated volume absorption or change in apical membrane water permeability
during aerosolisation, deposition of a constantly accumulating mass of salt to the surface of airway
epithelia is predicted to produce a linear increase in ASL volume. For all rates studied, the measured ASL
height deviated consistently from the predicted height (figure 2c–e). The deviation of measured ASL
height from predicted values could reflect active Na+ absorption, reductions in HBE water permeabilities
that govern rates of osmotically driven water flow to the HBE surface, or both.
With respect to the role of Na+ transport on ASL volume responses to HS administration, we speculated
that Na+ transport would modify the magnitude of HS-induced ASL volume expansion immediately after
initiation of HS administration. To experimentally investigate this possibility, ASL volume responses to the
low rate of HS administration (3 µg NaCl·cm−2·min−1) were measured in the presence and absence of a
selective ENaC blocker (VX-371; Vertex Pharmaceuticals, Boston, MA, USA). As compared to HS alone,
the co-administration of VX-371 (50 µg·mL−1) produced a more rapid and sustained ASL response during
nebulisation (figure 3a). A mathematical model of airway epithelial ion and water transport quantitatively
analysed the relationship between HS-mediated changes to ASL height and active Na+ absorption in the
presence and absence of ENaC blockade (figure 3b). The fit of the model to experimental data describing
ASL response for HS administration in the absence of ENaC inhibition was achieved by maintaining Na+
transport at basal rates during HS aerosolisation and increasing Na+ transport roughly five-fold during the
re-absorptive phase. The mathematical model replicated the effect of ASL kinetics with ENaC inhibition,
with a more rapid rate of accumulation and overshoot of ASL height, consistent with inhibition of active
Na+ absorption during HS administration.
Previous studies have demonstrated that HS can produce a reduction in cell volume [20, 21], which can
then inhibit cell water permeabilities [21–23]. Additionally, studies suggest that administration of
hypertonic saline also will result in inflammatory changes within the airway epithelia, particularly IL-8, a
known neutrophil chemoattractant [24–26]. Accordingly, we measured HBE cell volume responses and
IL-8 production to HS aerosol administration to test whether reductions in cell water permeabilities
blunted ASL responses to aerosolised HS and/or induced pro-inflammatory cytokines. Figure 4a shows
that cell height (a surrogate for cell volume) was reduced during and after HS nebulisation by ∼20% from
initial cell heights (p<0.01). In contrast, cell volume was not affected by nebulisation of isotonic saline.
These data suggest that deposition of luminal HS osmotically draws water from cells onto the surface via
apical membrane water channels. Figure 4b demonstrates cumulative IL-8 production by HBE 24 h after
nebulising HS or PBS control to airway surfaces. A stepwise increase in IL-8 production was noted with
increasing doses of HS compared with PBS control (statistically different from control at 18 µg dose and
bulk dosing).
The contribution of cellular water permeability to ASL volume responses was investigated further using a
pharmacological approach. Because mercury-sensitive water channels (aquaporins) have been identified in
the apical and basolateral membranes of HBE epithelia [27, 28], the role of these channels on
HS-mediated changes in ASL volume responses was evaluated experimentally. Because mercury has
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FIGURE 3 Effect of sodium reabsorption on hypertonic saline (HS)-mediated airway surface liquid (ASL) height. a) Experimental data of hypertonic
saline (at 8 µg NaCl·cm−2·min−1) in the absence and presence of a potent sodium channel blocker (VX-371 at 50 µg·mL-1); b) mathematical model
predictions of the HS effect with normal epithelial sodium channel conductance (GENaC) (consistent with experimental data) and 15% of normal
GENaC.
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As shown in figure 5a, both apical and basolateral mercury chloride (HgCl2) administration significantly
reduced ASL volume responses to aerosolised HS. Inhibition of apical aquaporins resulted in a smaller
decrease in cell height compared to basolateral aquaporin inhibition. These data suggest that in the setting
of aerosolised HS, cell volume homeostasis is dominated by the apical membrane water permeability
(figure 5b). Modelling studies mimicked the experimental data (figure 5c).
We hypothesised that persistent reduction in cell volumes observed after HS administration would limit the
ability of HBEs to respond to repeated administrations of HS. This hypothesis was tested by exposing HBE
cultures to sequential HS administrations (8 µg NaCl·cm−2·min−1), with the second administration delivered
15 min after ASL height had returned to baseline following the first HS dose. ASL height and AUC of the
second administration was significantly reduced compared to initial HS administration (figure 6a).
Next, we directly tested the hypothesis that the reduction in the effectiveness of the second HS
administration reflected reduced HBE cell water permeabilities consequent to cell volume reduction, rather
than persistent acceleration of Na+ transport. To test this notion, a small volume of hypotonic saline
(0.63% NaCl, 10 µL) was transiently added (3 min) to the apical surface of HBEs following the first
aerosolised HS administration. Application of the hypotonic saline bolus resulted in cell swelling (increase
in height 32±9 µm) that restored cell height to baseline levels. The interposition of the hypotonic bolus
was associated with a statistically larger response in ASL and AUC to the second HS administration
(figure 6b). In contrast, applying a bolus dose of isotonic saline (0.9% NaCl, 10 µL) produced neither cell
swelling nor a recovery in responsiveness to the subsequent HS challenge (figure 6c). Modelling this
phenomenon predicted that reduction in apical water permeability to ∼10% of baseline levels would
produce the AUC decrement with the second HS administration observed experimentally (figure 6d).
Next, we investigated whether the presence of hyperconcentrated mucus associated with muco-obstructive
diseases [30] alters the kinetics of HS-induced hydration, utilising HBE cultures exhibiting
hyperconcentrated mucus (12±4.3% solids). CF is the disorder best characterised by hyperconcentrated
mucus. However, other muco-obstructive diseases, e.g. primary ciliary dyskinesia [3] and non-CF
bronchiectasis [4] exhibit hyperconcentrated mucus, and we have previously shown that CF cells and
normal HBE in the presence of hyperconcentrated mucus behave similarly in response to nebulised
hypertonic saline [13]. Accordingly, we focused our studies of muco-obstructive disease mucus on normal
HBE with hyperconcentrated mucus to make the data relevant to other possible muco-obstructive lung
diseases. Pre-HS administration, ASL height in the hyperconcentrated mucus cultures was approximately
three-fold higher than the normal mucus cultures. Notably, the changes in ASL height with HS
administration were substantially increased in hyperconcentrated mucus cultures as compared to normal
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FIGURE 4 a) Cell volume changes in response to osmotic stimulus of hypertonic saline (HS) at varying HS deposition rates. A 20% decrease in cell
height in response to the hypertonic stimulus was observed at all rates, which was significantly different from baseline and isotonic (PBS) saline
administration (p<0.01 by Holm–Sidak method). Cell height did not recover during the time frame of the experiment (60 min). Cell volume
reduction was a consistent finding regardless of rate of HS administration. n=4 for each condition. b) Production of interleukin (IL)-8 in response
to increasing doses of nebulised or bulk HS. Statistically different from control (PBS) at the 18-µg dose and bulk dosing (100 µL of 7% HS).
#: p<0.002 by Holm–Sidak method; ***: p<0.001.
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the increased ASL volume immediately after cessation of nebulisation, the rate of reabsorption was slower
in hyperconcentrated versus normal mucus cultures (5.5 versus 2.8 µm·min−1, p=0.052; figure 7b). In the
hyperconcentrated mucus cultures, the total duration of HS-induced ASL volume expansion was
approximately double that of normal mucus cultures. Further, in repetitive HS administration protocols,
the second administration of HS produced an ASL response similar to the first administration (figure 7c).






















































































FIGURE 5 Incubation with mercury (Hg) chloride apically or basolaterally resulted in a diminished airway
surface liquid (ASL) response to aerosolised hypertonic saline (HS) (at 8 µg NaCl·cm−2·min−1) compared with
native cultures. a) Experimental data. p<0.001 via Holm–Sidak method for comparisons to control. b)
Mathematical model of experimental data. n=8 for each condition. c) Cell height change to aerosolised HS in
the absence (control) or presence of selective block of the apical or basolateral cell membrane with mercury
chloride (p<0.001 for all comparisons).
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response to HS (15±4.7% versus 23±5.7%) than in normal cultures, although this difference did not
achieve statistical significance.
The larger peak ASL response and slower absorption of NaCl and water in the hyperconcentrated versus
normal mucus cultures suggested that an additional force was governing water flux in the
hyperconcentrated mucus system. To generate an index of the magnitude of this effect, the predicted
versus measured ASL heights during HS administration were compared (figure 7d). The measured early
administration values were significantly closer to the predicted value for hyperconcentrated compared with
normal mucus cultures (figure 2c–e), suggesting that the presence of concentrated mucus generated
additional mucus-related osmotic forces that retarded fluid absorption [30].
Discussion
Our in vitro studies of clinically relevant rates of aerosolised HS delivered to HBE cultures with 2% mucus
solids revealed a rapid HS-induced expansion of ASL volume. This ASL expansion in response to HS
aerosols is similar to that reported in vivo in mice measured by synchrotron-based tomography and in
HBE cultures by optical coherence tomography [31, 32]. Furthermore, acute aerosolisation of HS has been
reported to reduce airway mucus concentrations in chronic obstructive pulmonary disease subjects [33].
Thus, the ASL expansion findings, juxtaposed to our findings that the osmolarity of ASL during HS
nebulisation probably does not exceed 370 mOsm·L−1 (see later), argues that the major effect of HS on
mucus clearance is via ASL volume expansion and mucus dilution.
The HS-induced ASL volume response was mediated by water flux in response to the deposition of
osmotically active NaCI on HBE surfaces. Two observations suggest that aquaporin-mediated
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FIGURE 6 Sequential airway surface liquid (ASL) volume responses to aerosolised 7% hypertonic saline (HS)
for 15 min (8 µg NaCl·cm−2·min−1). a) Sequential ASL volume responses to aerosolised HS. A smaller ASL
response to a second administration of aerosolised HS was observed when two identical HS doses were
separated by 15 min. Break in x-axis indicates time between two doses. For each dose, HS was nebulised at
8 µg NaCl·cm−2·min−1 and administered continuously for 15 min. The ASL height of the second peak was
∼60% of the first peak. p<0.001 by Mann–Whitney rank sum test. b) A hypotonic saline rinse was interposed
between HS administration. The hypotonic solution administration produced cellular swelling associated with
improved ASL volume responses to a subsequent administration of HS (∼140% of first dose). The difference in
response was statistically significant (p=0.002 via Mann–Whitney rank sum test) in favour of the
post-hypotonic peak. c) Interposition of an isotonic rinse between the first and second HS administration. The
same second-dose effect is not seen when doses of HS were separated by an isotonic saline bolus (p=0.78 by
Mann–Whitney rank sum test). ASL height of second peak persisted at ∼50% of the first peak. d) In a model
simulation, the water permeability of the human bronchial epithelial apical membrane during the second dose
was reduced to 10% of the basal water permeability. n=4 for each condition.
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lumen in response to HS was accompanied by a reduction in cell height/volume, suggesting intracellular
water moved into ASL. This notion is consistent with previous studies [21] that reported the
aquaporin-dominated apical membrane water permeability of HBE was ∼10-fold higher than the
basolateral membrane. Note that this configuration permits the use of changes in cell volume as an
“osmometer” to detect ASL osmolarity. The cell volume responses to HS aerosols suggest that ASL
achieved osmolarities of ∼370 mOsm·L−1 during HS administration (7% HS given at 7.7 µg
NaCl·cm−2·min−1), far less than achieved by direct HS additions. The second observation was that the ASL
responses to aerosolised HS were blocked by HgCl2, an inhibitor of aquaporin 3–5 known to be expressed
in HBEs. These data, along with the cell modelling data presented, strongly suggest that
aquaporin-mediated cellular water permeabilities participate in the ASL volume responses to aerosolised
HS (figure 4).
The effects of aerosolised HS on cell volume reduction and transepithelial Na+ transport probably explain
the discrepancy between the predicted ASL responses to deposition of HS on HBE surfaces and measured
responses. First, reductions in cell volume were associated with reductions in cell water permeabilities,
limiting water fluxes toward a hypertonic lumen. Second, as evidenced by a greater maximal response to
HS administration in the presence of an ENaC blocker, active Na+ transport removed a component of the
deposited NaCl during aerosol administration. An interesting observation that emerged from the
modelling of active Na+ transport responses to HS was that an increase in Na+ transport rates was required
to mimic the rate of ASL volume absorption post-cessation of aerosol. This effect probably reflects dilution
of local extracellular inhibitors of ENaC, e.g. ATP, that accelerated the rate of absorption during HS
administration [34].
A key issue with respect to HS therapeutic responses relates to the concentration of mucus on airway

























































































FIGURE 7 The effects of hyperconcentrated mucus on human bronchial epithelial (HBE) surfaces on nebulised
hypertonic saline (HS) (at 8 µg NaCl·cm−2·min−1) in inducing airway surface liquid (ASL) volume responses.
a) In the normal (2% mucus) state, there was a three-fold increase in ASL volume during nebulisation. HBE
cultures with hyperconcentrated mucus (12%) (cystic fibrosis (CF)-like) exhibited a seven-fold increase in ASL
above baseline ASL. In addition, the duration of ASL being increased above basal levels was increased in
hyperconcentrated mucus HBE cultures. b) Rates of reabsorption (time to baseline ASL, in µm·min−1) were
significantly different between the normal and the hyperconcentrated mucus cultures. p=0.052 by Mann–
Whitney rank sum testing. c) Two sequential doses of HS administered to hyperconcentrated cultures. ASL
height difference favours the second dose (p<0.001). d) Theoretical expected rise in ASL height if all salt
deposited remained on the surface and resulted in an equimolar flux of water into the ASL and the actual
change in ASL height observed during experiments. Compare with figure 2c–e; in the presence of an intact
mucus layer (12% solids), actual and expected ASL height more closely approximated each other early in the
HS delivery interval.
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heights, a longer duration of ASL hydration to a single HS administration, and larger responses to
repetitive doses of HS. We postulate that mucus acts as a “sponge”, providing a concentration-dependent
polymer gel-mediated osmotic driving force, added to that of HS-induced osmotic gradients,
which modulates maximal mucus/ASL heights on the HBE surface. The increased durability of the
ASL expansion in response to aerosolised HS in hyperconcentrated mucus cultures parallels the longer
duration of action of HS in CF as compared to normal subjects observed in in vivo mucociliary clearance
studies [5, 35].
In addition, our studies were designed to identify strategies to increase the effectiveness of aerosolised HS
to expand ASL hydration, including studies of HS delivery rates and repetitive dosing. We found that very
slow rates of HS delivery were relatively ineffective. We speculate that this finding reflects the fact that
NaCl deposition rates were similar to rates of endogenous active transepithelial Na+ absorption [36].
Delivery of HS at rates approximating a jet nebuliser were effective in increasing ASL hydration, but a
further increase in efficacy was not observed with faster rates mimicking vibrating mesh nebulisers. The
absolute decrease in AUC and the slowing of ASL volume expansion observed towards the end of rapid
HS administration (18 µg NaCl·cm−2·min−1) are consistent with large reductions in transepithelial water
permeabilities. Based on our IL-8 measurements and the pro-inflammatory nature of this cytokine, it is
possible that faster rates of nebulisation could be detrimental.
An important observation pertinent to HS dosing frequency was that HBE cell heights did not return to
baseline levels for 4 h following HS administration. We speculate that the absence of cell volume regulation
mechanisms reflected decreased water permeabilities. It is likely that the delay in return of apical water
permeability after HS accounted for the blunted response to second HS administrations on HBE cultures
with normal mucus (figure 5). Importantly, epithelial cell swelling induced by hypotonic saline restored
second HS responses. These data suggest that novel strategies may be required to optimise the effectiveness
of repetitive HS dosing in patients with milder lung disease. In contrast, repetitive HS dosing in subjects
with severe (12% mucus solids) disease may be an effective strategy.
In conclusion, ASL volume of HBE cultures with normal mucus concentrations increased in response to
nebulised HS delivered at rates similar to those delivered clinically, but reabsorption began immediately
with termination of nebulisation. Neither nebulising faster nor slower improved ASL hydration. However,
the effects of aerosolised HS were more pronounced and prolonged in HBE cultures with
hyperconcentrated mucus, probably reflecting the increased osmotic forces generated by concentrated
mucus. These data predict a prolonged duration of HS action in patients with muco-obstructive diseases.
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